سعر انفكتوكيور 125مجم5مل معلق 60 مل 2024

Infectocure 125mg/5ml oral suspension 60 ml: clarithromycin 125 mg/5 ml oral suspension, a macrolide antibiotic marketed in Egypt by Egpi.

• Acute bacterial exacerbation of chronic bronchitis (mild to moderate).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Acute maxillary sinusitis.Population: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)
• Community-acquired pneumonia.Population: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)

• Most frequent: abdominal pain, diarrhoea, nausea, vomiting and dysgeusia (taste perversion); also dyspepsia, abnormal liver function tests, headache, insomnia and rash.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to clarithromycin, erythromycin or any macrolide antibiotic.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant cisapride or pimozide (QT prolongation, ventricular arrhythmias).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Severe acute hypersensitivity reactions (anaphylaxis, SJS, TEN, DRESS, Henoch-Schonlein purpura): discontinue and treat.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and torsades de pointes: avoid in patients with known QT prolongation, uncorrected hypokalaemia/hypomagnesaemia, bradycardia or with class IA/III antiarrhythmics.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity (including hepatic failure): discontinue if signs of hepatitis occur.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• ColchicineIncreased colchicine exposure with life-threatening toxicity; contraindicated in renal/hepatic impairment, otherwise reduce colchicine dose.DailyMed (U.S. National Library of Medicine)
• HMG-CoA reductase inhibitors (lovastatin, simvastatin; atorvastatin, pravastatin)Rhabdomyolysis risk; lovastatin/simvastatin contraindicated; use lowest dose of atorvastatin (max 20 mg) or pravastatin (max 40 mg).DailyMed (U.S. National Library of Medicine)
• Class IA/III antiarrhythmics and other QT-prolonging drugsAdditive QT prolongation; avoid.DailyMed (U.S. National Library of Medicine)

• Not recommended for use in pregnant women except where no alternative therapy is appropriate; clarithromycin caused adverse developmental outcomes (malformations, embryo-fetal loss) in animal studies.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Clarithromycin and its active metabolite are excreted in human milk; the estimated infant dose is less than 2% of the maternal weight-adjusted dose. Weigh benefits against risks.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Clarithromycin: Binds the 50S ribosomal subunit of susceptible bacteria and inhibits protein synthesis.